From Spectroglyph, LLC
Due to its ability to accurately identify both arrays of biomolecules, and/or low abundance biomolecules, hybrid mass spectrometry has become recognized as the gold standard for the identification of commercially significant biomarkers. The detection of these biomarkers in samples such as tissues, cells, and a variety of human bodily fluids facilitates the early detection of diseases and helps identifying individualized therapies for patients. As a result, hybrid mass spectrometry, particularly when integrated with bioinformatics tools, is seeing exponential growth in the validation and discovery of biomarkers relevant to disease detection, disease monitoring, drug response and drug safety prediction, and personalized medicine.
Spectroglyph is committed to providing analytical services at unsurpassed sensitivity and selectivity using state-of-the-art proprietary technologies.